



*Prevention
and early
treatment of
COVID-19*



I-MASK+
MATH+



Dr. Paul Marik




Dr. G. Umberto Meduri



Dr. Jose Iglesias



Dr. Pierre Kory



Dr. Joe Varon




Dr. Eivind Vinjevoll




Dr. Scott Mitchell



Dr. Keith Berkowitz



Dr. Howard Kornfeld



Dr. Fred Wagshul

FOUNDING MEMBERS

- March 2020
- FLCCC formed by leading Critical Care specialists
- Non-profit
- Mission: Develop effective COVID-19 treatment protocols
- Prevent COVID-19 transmission
- Improve patient outcomes



Intravenous **M**ethylprednisolone
High Dose Intravenous **A**scorbic Acid (Vitamin C)
Thiamine (Vitamin B1)
Low Molecular Weight **H**eparin
+
Statin – Zinc – Vitamin D – Famotidine – Melatonin – Magnesium

*Hospital
protocol
created by the
FLCCC in
March 2020*

December 4, 2020

A CALL-TO-ACTION
IN A TIME OF
A NATIONAL AND
GLOBAL HEALTH
CRISIS



NATIONAL CALL-TO-ACTION

Vaccines are coming,
but they are only
part of the solution.



Electronic Press Kit:

flccc.net

I-MASK+
MATH+

Treatment delay →



Pre-Exposure Prophylaxis

regularly take medication in advance to prevent or minimize infections

Post-Exposure Prophylaxis

treat shortly after exposure to minimize infection

Early Treatment

treat immediately on symptoms or shortly thereafter

Late Treatment

late stage after disease has progressed

I-MASK+

PROPHYLAXIS & EARLY OUTPATIENT TREATMENT PROTOCOL FOR COVID-19

PROPHYLAXIS PROTOCOL

Ivermectin	<i>Prophylaxis for high risk individuals</i> 0.2 mg/kg* – one dose on day 1 and day 3, then take one dose every 4 weeks <i>Post COVID-19 exposure prophylaxis**</i> 0.2 mg/kg* – one dose on day 1 and day 3
Vitamin D3	1,000–3,000 IU/day
Vitamin C	1,000mg twice a day
Quercetin	250mg/day
Zinc	50mg/day
Melatonin	6mg before bedtime (causes drowsiness)

EARLY OUTPATIENT PROTOCOL***

Ivermectin	0.2 mg/kg* – one dose on day 1 and day 3
Vitamin D3	4,000 IU/day
Vitamin C	2,000 mg 2–3 times daily
Quercetin	250mg twice a day
Zinc	100mg/day
Melatonin	10mg before bedtime
Aspirin	325mg/day (unless contraindicated)



IVERMECTIN



- 40-year-old anti-parasitic drug
- Discovery awarded Nobel Prize in 2015
- On the W.H.O.'s list of “essential medicines.”

IVERMECTIN

Used safely by 3.7 billion
people worldwide.



IVERMECTIN

High activity against COVID19

- Pre-Exposure
- Post-Exposure
- Early Symptoms
- Late Stage Disease



IVERMECTIN


New and compelling data has emerged since August—the last time the N.I.H. updated their recommendations



Electronic Press Kit:

flccc.net

Studies show
consistent,
reproducible
efficacy of
Ivermectin.





Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019

The ICON Study

Juliana Cepelowicz Rajter, MD; Michael S. Sherman, MD, FCCP; Naaz Fatteh, MD; Fábio Vogel, MD; Jamie Sacks, PharmD; and Jean-Jacques Rajter, MD

IVERMECTIN




Prophylaxis Trials of > 1,100 patients

- 3 Randomized Controlled Trials
- 1 Observational Trial

Prophylaxis of household contacts of COVID-19 patients
Randomized, Controlled Trial
Zagazig University, Egypt

**Percentage
of household
contacts with
COVID-19
symptoms**




$p < .05$

Prophylaxis of health care workers study

Observational Controlled Trial

All India Institute of Medical Sciences


Percentage of
health care
workers who
contracted
COVID-19



Prophylaxis of household and health care worker contacts of COVID-19 patients


Randomized Controlled Trial

Percentage of health care and household contacts who contracted COVID-19



Prophylaxis of 229 Healthy Citizens Randomized Controlled Trial – Argentina

**Percentage of
healthy citizens
who contracted
COVID-19 after
28 days**





WITH IVERMECTIN
 $1/69=1.4\%$ infection

Long Term Care Facility A



WITHOUT IVERMECTIN
 $22/100=22\%$ infection

Long Term Care Facility B+C+D

IVERMECTIN



Outpatient Trials – 500 Patients

- 3 Randomized Controlled Trials
 - Large Case Series

IVERMECTIN



Hospitalized Patient Trials


4 Randomized Controlled Trials > 800 patients

4 Observational Controlled Trials > 2000 patients

**All available
clinical trial results
show major benefits
of Ivermectin
in prevention and
treatment**


Treatment time	Number of studies reporting positive results	Total number of studies	Percentage of studies reporting positive results
Early treatment	3	3	100%
Late treatment	12	12	100%
Pre-Exposure Prophylaxis	4	4	100%
Post-Exposure Prophylaxis	2	2	100%
All studies	21	21	100%

Deaths in patients over 60 among 8 Peruvian states after deploying mass ivermectin treatment




Decreases in COVID-19 Case Fatality Rates in Peruvian patients over 60

Figure 13. Case Fatality Rate in population older than 60 years old for eight Peruvian states deploying mass ivermectin treatment



Total deaths, case incidence and case fatality for COVID-19 in populations older than 60 years old for eight states deploying early mass ivermectin treatments vs Lima in Peru.



Data Analyst: Juan Chamie juanjchamie@gmail.com

Sources: Total Deaths: cloud.minsa.gob.pe/s/NctBnHXDnncgWAg/download; datosabiertos.gob.pe/group/datos-abiertos-de-covid-19


COVID-19 in MEXICO

Source: <https://www.gob.mx/salud/documentos/datos-abiertos-152127> Questions?

Analyst: Juan Chamie juanjchamie@gmail.com


Deaths per 100,000 people before August 1st 2020

Deaths per 100,000 people after August 1st 2020




PARAGUAY

Weekly COVID-19 Deaths



Weekly COVID-19 Cases



Electronic Press Kit:

flccc.net

NATIONAL CALL-TO-ACTION

National & Global Health Authorities:

Review Recent Clinical Trials Evidence
Demonstrating Clinical Benefits of IVERMECTIN



Failed and successful Rx for COVID-19 by phase of illness*

	Pre-exposure/ Post-Exposure/ Incubation	Symptomatic Phase	Pulmonary/ inflammatory phase
Hydroxychloroquine	Unclear benefit	No benefit	?Trend to harm
Remdesivir	n/a	?? Reduced time to recovery No mortality benefit	No benefit
Lopinavir-Ritonavir	n/a	No benefit	No benefit
Interferon α/β	Inhaled ? Benefit	No benefit	?Trend harm
Tocilizumab	n/a	n/a	No Benefit
Convalescent Serum	n/a	Unlikely	No Benefit
Corticosteroids	n/a	Trend to harm	BENEFIT
Ivermectin	BENEFIT	BENEFIT	BENEFIT

* Based on Randomized Controlled Trials

Frontline Covid-19 Critical Care Alliance

The I-MASK+ protocol will revolutionize the treatment of COVID-19"

Dr. Paul Marik (Oct. 30, 2020)

The Front Line Covid-19 Critical Care Alliance has now developed a prophylactic and early outpatient combination treatment protocol for COVID-19 called I-Mask+. This protocol is centered around the use of Ivermectin, a well-known anti-parasite drug with recently discovered anti-viral and anti-inflammatory properties and a rapidly growing published medical evidence base demonstrating its unique and highly potent ability to inhibit SARS-CoV-2 replication.

Please visit these links to get the full picture:

- [I-MASK+ Prophylaxis & Early Outpatient Treatment Protocol for COVID-19 \(PDF\)](#)
- [Our comprehensive review of the emerging evidence for Ivermectin use in our I-MASK+ protocol \(PDF, continuously updated\)](#)
- [A concise summary of the scientific review on ivermectin above \(PDF, continuously updated\)](#)
- [Dr. Paul Marik's comprehensive meta-analysis of COVID-19 therapeutics \(PDF\)](#)

LATEST UPDATES

Dec. 3, 2020 [FLCCC Release]

An FLCCC Alliance guide to the management of COVID-19 (PDF)

An overview of the MATH+ and I-MASK+ protocols

Nov. 25, 2020 [FLCCC News Release]

FLCCC Alliance Press Conference on Dec. 4, 2020 (PDF)

United Memorial Medical Center in Houston, Texas, 10:30 am

Nov. 22, 2020 [TMBS]

A doctor tells how MATH+ saved hospitals and hundreds of lives, and how I-MASK+ could do even more.

Excerpt from the interview with Dr. Eric Osgood (The Michael Brooks Show)

Nov. 13, 2020 [Associazione Naso Sano]

Invited Grand Rounds on ivermectin by Dr. Pierre Kory (virtual lecture)

Ivermectin in the prophylaxis and



Image: Dr. Joseph Varon (FLCCC Alliance) visits a patient during rounds in his COVID-19 unit at United Memorial Medical Center, Houston, TX, USA, July 6, 2020. Photo: © 2020 David J. Phillip - AP/PA

The FLCCC Alliance

As a group of colleagues with over 200 years of combined experience in Critical Care and Emergency Medicine, as well as long-standing shared interests in developing effective treatments for critical illnesses including sepsis, we, the **FLCCC Alliance**, formed a working group devoted to creating a

NATIONAL CALL-TO-ACTION

Following swift validation of evidence,
health authorities are urged to issue guidelines
for health care providers to prescribe

IVERMECTIN





I-MASK+

PROPHYLAXIS & EARLY OUTPATIENT
TREATMENT PROTOCOL FOR COVID-19

I-MASK+ will change the face
of this disease worldwide.

Electronic Press Kit:

flccc.net